Durvalumab-induced immune-related hepatitis in a patient with non-small cell lung cancer

Masakatsu Nakamura; Toshimi Otsuka; Ranji Hayashi; Tomoe Horita; Masafumi Ota; Naoko Sakurai; Hikaru Takano; Tasuku Hayashi; Motona Kumagai; Sohsuke Yamada; Tomiyasu Arisawa

doi:10.2169/internalmedicine.4699-20

Durvalumab-induced immune-related hepatitis in a patient with non-small cell lung cancer

Masakatsu Nakamura
, Toshimi Otsuka
, Ranji Hayashi
, Tomoe Horita
, Masafumi Ota
, Naoko Sakurai
, Hikaru Takano
, Tasuku Hayashi
, Motona Kumagai
, Sohsuke Yamada
, Tomiyasu Arisawa

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m2), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged.

Original language	English
Pages (from-to)	2711-2717
Number of pages	7
Journal	Internal Medicine
Volume	59
Issue number	21
DOIs	https://doi.org/10.2169/internalmedicine.4699-20
Publication status	Published - 01-11-2020
Externally published	Yes

All Science Journal Classification (ASJC) codes

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.4699-20

Cite this

@article{91f47207ecb44bb98f34e0e3aa4cc381,

title = "Durvalumab-induced immune-related hepatitis in a patient with non-small cell lung cancer",

abstract = "We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m2), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged.",

keywords = "durvalumab, immune-related hepatitis, non-small cell lung cancer",

author = "Masakatsu Nakamura and Toshimi Otsuka and Ranji Hayashi and Tomoe Horita and Masafumi Ota and Naoko Sakurai and Hikaru Takano and Tasuku Hayashi and Motona Kumagai and Sohsuke Yamada and Tomiyasu Arisawa",

year = "2020",

month = nov,

day = "1",

doi = "10.2169/internalmedicine.4699-20",

language = "English",

volume = "59",

pages = "2711--2717",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "21",

}

TY - JOUR

T1 - Durvalumab-induced immune-related hepatitis in a patient with non-small cell lung cancer

AU - Nakamura, Masakatsu

AU - Otsuka, Toshimi

AU - Hayashi, Ranji

AU - Horita, Tomoe

AU - Ota, Masafumi

AU - Sakurai, Naoko

AU - Takano, Hikaru

AU - Hayashi, Tasuku

AU - Kumagai, Motona

AU - Yamada, Sohsuke

AU - Arisawa, Tomiyasu

PY - 2020/11/1

Y1 - 2020/11/1

N2 - We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m2), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged.

AB - We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m2), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged.

KW - durvalumab

KW - immune-related hepatitis

KW - non-small cell lung cancer

UR - https://www.scopus.com/pages/publications/85094983015

UR - https://www.scopus.com/pages/publications/85094983015#tab=citedBy

U2 - 10.2169/internalmedicine.4699-20

DO - 10.2169/internalmedicine.4699-20

M3 - Article

C2 - 32669493

AN - SCOPUS:85094983015

SN - 0918-2918

VL - 59

SP - 2711

EP - 2717

JO - Internal Medicine

JF - Internal Medicine

IS - 21

ER -

Durvalumab-induced immune-related hepatitis in a patient with non-small cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this